The National Cancer Institute, a branch of the National Institutes of Health, has awarded an $11.3 million, five-year competitive grant renewal to the Pacific Northwest Prostate Cancer Specialized Programs of Research Excellence (SPORE).
Drs. Martin Gleave and Christopher Ong of the Vancouver Prostate Centre are co-leaders of one of five projects awarded funding in this grant.
The five projects are set within a program involving four institutions in Seattle, Portland and Vancouver, B.C.. This consortium has been led by the Fred Hutchinson Cancer Research Center since it was established in 2002 with a $12.7 million, five-year NCI grant. An additional five-year, $11.8 million competing NCI grant renewal was awarded to the Hutch in 2007, reinforcing the reputation of the Pacific Northwest consortium as a major force in prostate cancer research.
This consortium aims to unravel the molecular mechanisms underlying the development and progression of prostate cancer and to develop new therapeutic strategies that use precision-medicine approaches to improve survival and reduce treatment-related side effects. “Precision medicine” is guided by the unique genetic and molecular signatures of each patient’s cancer to deliver the most effective treatment.
The Pacific Northwest Prostate Cancer SPORE continuation grant represents a coordinated effort between four institutions, each with established programs and strengths in translational prostate cancer research.
Click here for further information. (PDF opens in new window)